{"id":1234202,"date":"2023-06-02T14:17:11","date_gmt":"2023-06-02T13:17:11","guid":{"rendered":"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/"},"modified":"2023-06-02T14:17:11","modified_gmt":"2023-06-02T13:17:11","slug":"innovative-heart-condition-drug-recommended-for-nhs-patients","status":"publish","type":"post","link":"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/","title":{"rendered":"Innovative heart condition drug recommended for NHS patients"},"content":{"rendered":"<p> <script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- newscabal uk text -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:inline-block;width:728px;height:90px\"\r\n     data-ad-client=\"ca-pub-8162386273903324\"\r\n     data-ad-slot=\"3688094655\"><\/ins>\r\n<script>\r\n(adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><br \/>\n<br \/><img decoding=\"async\" src=\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg\" \/><\/p>\n<div id=\"main\">\n<div class=\"sc-ldgPui iFAktg\"><span class=\"sc-iSfpOV buoAuz\">A<\/span><\/p>\n<p> first-of-its-kind treatment targeting a chronic heart disease could offer a \u201cgreater hope\u201d to thousands of people living with the condition.<\/p>\n<\/div>\n<p>The National Institute for Health and Care Excellence (Nice) has approved the use of mavacamten in draft guidance to the <a href=\"https:\/\/www.standard.co.uk\/topic\/nhs\">NHS<\/a>.<\/p>\n<aside\/>\n<p>It would be used to treat those with obstructive hypertrophic cardiomyopathy (HCM), with about 7,000 people expected to benefit.<\/p>\n<p>The drug \u2013 also known as Camzyos \u2013 is the first to specifically target the chronic disease, which in 50% of cases is caused by an inherited genetic mutation.<\/p>\n<p>It would be prescribed alongside other medicines such as beta-blockers, non-dihydropyridine calcium channel blockers or disopyramide.<\/p>\n<aside data-auto-link=\"true\" data-is-watch-more=\"false\" class=\"sc-bfGmnW gwEtkA item-count-4 related\">\n<h3 class=\"sc-jAjkD jhwPFd\">Read More<\/h3>\n<\/aside>\n<div class=\"sc-hnmMDg jDXMwT\">\n<p>Mavacamten provides a real breakthrough, and it is good to see that its approval has been fast-tracked by Nice so patients can benefit from an improved quality of life sooner<\/p>\n<\/div>\n<p>Those with obstructive HCM have excessive heart muscle contractions, which cause the organ to become thickened and stiff and stop it from pumping sufficient blood to meet the body\u2019s needs.<\/p>\n<aside\/>\n<p>Symptoms include tiredness, dizziness, shortness of breath, chest pains and heart palpitations, and it can lead to complications such as an irregular heartbeat, heart failure, stroke and sudden cardiac death.<\/p>\n<p>In its draft guidance, <a href=\"https:\/\/www.standard.co.uk\/topic\/nice\">Nice<\/a> said clinical trials suggested that mavacamten plus standard care is more effective than standard care alone and could delay the need for surgery.<\/p>\n<p><interaction class=\"apester-media\" data-token=\"610152711b664d000c5ab952\"\/><\/p>\n<p>Helen Knight, director of medicines evaluation at Nice, said the move is \u201canother example\u201d of the organisation\u2019s \u201ccommitment to drive early access to innovative new treatments\u201d.<\/p>\n<p>Mavacamten is yet to be licensed for use in the UK and Nice will not publish its final guidance on the drug until it has been approved.<\/p>\n<p>Knight added: \u201cObstructive hypertrophic cardiomyopathy is a disease for which, until now, there has been no specific treatment that targets its underlying cause. It has a very high and wide-ranging impact on quality of life and because it can develop at any age, it can occur in younger people who may formerly have had very active lifestyles.<\/p>\n<p>\u201cThe treatments currently used to try to manage symptoms are associated with side effects and are often ineffective. We\u2019re therefore pleased to be able to recommend a treatment that has the potential to alter the course of obstructive hypertrophic cardiomyopathy and offer greater hope to people with it.\u201d<\/p>\n<p>Professor Sir Nilesh Samani, medical director at the <a href=\"https:\/\/www.standard.co.uk\/topic\/british-heart-foundation\">British Heart Foundation<\/a>, said: \u201cThis is very welcome news for patients with obstructive HCM, who often have debilitating symptoms that are not improved by current treatments.<\/p>\n<p>\u201cMavacamten provides a real breakthrough, and it is good to see that its approval has been fast-tracked by Nice so patients can benefit from an improved quality of life sooner.\u201d<\/p>\n<\/div>\n<p><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block; text-align:center;\"\r\n     data-ad-layout=\"in-article\"\r\n     data-ad-format=\"fluid\"\r\n     data-ad-client=\"ca-pub-8162386273903324\"\r\n     data-ad-slot=\"7859258044\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><br \/>\n<br \/><a href=\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html\">READ SOURCE<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A first-of-its-kind treatment targeting a chronic heart disease could offer a \u201cgreater hope\u201d to thousands of people living with the condition. The National Institute for Health and Care Excellence (Nice) has approved the use of mavacamten in draft guidance to the NHS. It would be used to treat those with obstructive hypertrophic cardiomyopathy (HCM), with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1234203,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_oct_exclude_from_cache":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-1234202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Innovative heart condition drug recommended for NHS patients - Business Telegraph<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovative heart condition drug recommended for NHS patients - Business Telegraph\" \/>\n<meta property=\"og:description\" content=\"A first-of-its-kind treatment targeting a chronic heart disease could offer a \u201cgreater hope\u201d to thousands of people living with the condition. The National Institute for Health and Care Excellence (Nice) has approved the use of mavacamten in draft guidance to the NHS. It would be used to treat those with obstructive hypertrophic cardiomyopathy (HCM), with [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html\" \/>\n<meta property=\"og:site_name\" content=\"Business Telegraph\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-02T13:17:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"businesstelegraph\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"businesstelegraph\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/\"},\"author\":{\"name\":\"businesstelegraph\",\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/person\/0a3a6a0f58402f1f2af94e02d0987b78\"},\"headline\":\"Innovative heart condition drug recommended for NHS patients\",\"datePublished\":\"2023-06-02T13:17:11+00:00\",\"dateModified\":\"2023-06-02T13:17:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/\"},\"wordCount\":459,\"publisher\":{\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg\",\"articleSection\":[\"Health\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/\",\"url\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html\",\"name\":\"Innovative heart condition drug recommended for NHS patients - Business Telegraph\",\"isPartOf\":{\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg\",\"datePublished\":\"2023-06-02T13:17:11+00:00\",\"dateModified\":\"2023-06-02T13:17:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage\",\"url\":\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg\",\"contentUrl\":\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.businesstelegraph.co.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovative heart condition drug recommended for NHS patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#website\",\"url\":\"https:\/\/www.businesstelegraph.co.uk\/\",\"name\":\"Business Telegraph UK\",\"description\":\"business, tech and industry news\",\"publisher\":{\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.businesstelegraph.co.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#organization\",\"name\":\"Business Telegraph UK\",\"url\":\"https:\/\/www.businesstelegraph.co.uk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2024\/03\/business-telegraph-LOGO.png\",\"contentUrl\":\"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2024\/03\/business-telegraph-LOGO.png\",\"width\":500,\"height\":177,\"caption\":\"Business Telegraph UK\"},\"image\":{\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/person\/0a3a6a0f58402f1f2af94e02d0987b78\",\"name\":\"businesstelegraph\",\"url\":\"https:\/\/www.businesstelegraph.co.uk\/author\/businesstelegraph\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovative heart condition drug recommended for NHS patients - Business Telegraph","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html","og_locale":"en_GB","og_type":"article","og_title":"Innovative heart condition drug recommended for NHS patients - Business Telegraph","og_description":"A first-of-its-kind treatment targeting a chronic heart disease could offer a \u201cgreater hope\u201d to thousands of people living with the condition. The National Institute for Health and Care Excellence (Nice) has approved the use of mavacamten in draft guidance to the NHS. It would be used to treat those with obstructive hypertrophic cardiomyopathy (HCM), with [&hellip;]","og_url":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html","og_site_name":"Business Telegraph","article_published_time":"2023-06-02T13:17:11+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg","type":"image\/jpeg"}],"author":"businesstelegraph","twitter_card":"summary_large_image","twitter_misc":{"Written by":"businesstelegraph","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#article","isPartOf":{"@id":"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/"},"author":{"name":"businesstelegraph","@id":"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/person\/0a3a6a0f58402f1f2af94e02d0987b78"},"headline":"Innovative heart condition drug recommended for NHS patients","datePublished":"2023-06-02T13:17:11+00:00","dateModified":"2023-06-02T13:17:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/"},"wordCount":459,"publisher":{"@id":"https:\/\/www.businesstelegraph.co.uk\/#organization"},"image":{"@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage"},"thumbnailUrl":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg","articleSection":["Health"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.businesstelegraph.co.uk\/innovative-heart-condition-drug-recommended-for-nhs-patients\/","url":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html","name":"Innovative heart condition drug recommended for NHS patients - Business Telegraph","isPartOf":{"@id":"https:\/\/www.businesstelegraph.co.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage"},"image":{"@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage"},"thumbnailUrl":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg","datePublished":"2023-06-02T13:17:11+00:00","dateModified":"2023-06-02T13:17:11+00:00","breadcrumb":{"@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#primaryimage","url":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg","contentUrl":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2023\/06\/1685733895_Innovative-heart-condition-drug-recommended-for-NHS-patients.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.standard.co.uk\/news\/health\/nice-nhs-british-heart-foundation-b1085268.html#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.businesstelegraph.co.uk\/"},{"@type":"ListItem","position":2,"name":"Innovative heart condition drug recommended for NHS patients"}]},{"@type":"WebSite","@id":"https:\/\/www.businesstelegraph.co.uk\/#website","url":"https:\/\/www.businesstelegraph.co.uk\/","name":"Business Telegraph UK","description":"business, tech and industry news","publisher":{"@id":"https:\/\/www.businesstelegraph.co.uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.businesstelegraph.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.businesstelegraph.co.uk\/#organization","name":"Business Telegraph UK","url":"https:\/\/www.businesstelegraph.co.uk\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/logo\/image\/","url":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2024\/03\/business-telegraph-LOGO.png","contentUrl":"https:\/\/www.businesstelegraph.co.uk\/wp-content\/uploads\/2024\/03\/business-telegraph-LOGO.png","width":500,"height":177,"caption":"Business Telegraph UK"},"image":{"@id":"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.businesstelegraph.co.uk\/#\/schema\/person\/0a3a6a0f58402f1f2af94e02d0987b78","name":"businesstelegraph","url":"https:\/\/www.businesstelegraph.co.uk\/author\/businesstelegraph\/"}]}},"_links":{"self":[{"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/posts\/1234202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/comments?post=1234202"}],"version-history":[{"count":0,"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/posts\/1234202\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/media\/1234203"}],"wp:attachment":[{"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/media?parent=1234202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/categories?post=1234202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businesstelegraph.co.uk\/wp-json\/wp\/v2\/tags?post=1234202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}